[{"Physician_Profile_ID": "1057493", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Eli Lilly and Company", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IN", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000088", "Total_Amount_of_Payment_USDollars": "4561.05", "Date_of_Payment": "07/24/2015", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "263815028", "Name_of_Associated_Covered_Drug_or_Biological1": "TRULICITY", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "THIS ACTIVE SURVEILLANCE PROGRAM WILL MONITOR FOR ANY SIGNAL INDICATING A POSSIBLE ASSOCIATION BETWEEN TREATMENT WITH LONG-ACTING GLP-1 RAS AND THE DEVELOPMENT OF MTC IN THE UNITED STATES POPULATION", "Research_Information_Link": "", "Context_of_Research": "The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."}, {"Physician_Profile_ID": "1057493", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Eli Lilly and Company", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IN", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000088", "Total_Amount_of_Payment_USDollars": "353.30", "Date_of_Payment": "04/06/2015", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "263815030", "Name_of_Associated_Covered_Drug_or_Biological1": "TRULICITY", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "THIS ACTIVE SURVEILLANCE PROGRAM WILL MONITOR FOR ANY SIGNAL INDICATING A POSSIBLE ASSOCIATION BETWEEN TREATMENT WITH LONG-ACTING GLP-1 RAS AND THE DEVELOPMENT OF MTC IN THE UNITED STATES POPULATION", "Research_Information_Link": "", "Context_of_Research": "The amount reported represents either an aggregate of cash payments -e.g. clinical study services, reimbursements for expenses or pass-through costs- or an aggregate of in-kind value -e.g. supplies, equipment- provided by Lilly or by a third party vendor in connection with clinical studies during the reporting period.  For available study details, please visit clinicaltrials.gov."}]